Evaluating community pharmacists' perceptions and practices on generic medicines: A pilot study from Peninsular Malaysia

Journal of Generic Medicines

Volumn 5, Issue 4, 2008, Pages 315-330

  din Babar, Zaheer Ud ^a   Awaisu, Ahmed ^b  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54749158601     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/jgm.2008.10     Document Type: Article

References (28)

1. Babar, Z. U. D., Ibrahim, M. I. M., Singh, H., Bukahri, N. I. & Creese, A. (2007). Evaluating drug prices, availability, affordability, and price components: Implications for access to drugs in Malaysia. PLoS Med 4(3), e82, doi:10.1371/journal.pmed.0040082.
2. Quick, J. D., Rankin, J. R., Laing, R. O., O'Connor, R. W., Hogerzeil, H. V., Dukes, M. N. & Garnett, A., (eds.)(1997). Managing Drug Supply 2nd edn., Kumarian Press, West Hartford, CT, pp. 7-9.
3. Goh, AI., Faridah, A., Rosminah, M. D., Nour Hanah, O. & Noor Aini, Z. (2007). Expenditure on medicines in Malaysia: Estimates from Malaysian statistics on medicines 2005. 7th MOH-AAM Scientific Meeting 20007.
4. Malaysia. Industry Forecast December (2005): www.eiu.com006The Economist Intelligence Unit Limited.
5. Product Registration and Post Market surveillance in Malaysia - An Overview. Consumer Medicines Surveillance Seminar, National Pharmaceutical Control Bureau, 9th January, 2007, Ministry of Health, Malaysia.
6. Malaysia Pharmaceuticals and Healthcare, Strategic Report. Business Monitor, January 2007. ISBN 1748-1996, http://www.piribo.com/ publications/country/asia_pacific/malaysia/ malaysia_pharmaceuticals_healthcare.html.
7. Azmi, I. M. & Alavi, R. (2001). TRIPS, patents, technology transfer, foreign direct investment and the pharmaceutical industry in Malaysia. J. World Intellect. Prop. 4, 947-974.
8. Babar, Z. U., Ibrahim, M. I. M. & Bukhari, N. I. (2005). A pricing analysis of cardiovascular and blood products after privatization of drug distribution system in Malaysia. J. Pharm. Finance Econ. Policy 14, 3-25.
9. McFadyen, J. E. (2004). International Drug Price Indicator Guide 2003 Management Sciences for Health, Boston, pp. E3-p2-18.
10. Gelders, S., Ewen, M., Noguchi, N. & Laing, R. (2006). Price, availability and affordability: An international comparison of chronic disease medicines. World Health Organization and Health Action International, Cairo, 2006. Available at: http://mednet3.who.int/ medprices/CHRONIC.pdf, accessed 20th October, 2007.
11. Babar, Z. U., Ibrahim, M. I. M. & Bukhari, N. I. (2005). Medicine utilization and pricing in Malaysia: The findings of a household survey. J. Gen. Med. 2(1), 47-61.
12. Ioannides-Demos, L. L., Ibrahim, M. I. M. & McNeil, J. J. (2002). Reference-based pricing schemes - Effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 20 9), 577-591.
13. King, D. R. & Kanavos, P. (2002). Encouraging the use of generic medicines: Implications for transition economies. Croat. Med. J. 43(4), 462-469.
14. Cox, E., Behm, A., Mager, D. & Miller, S. (2004). Generic drug usage report (homepage on the internet). No date. (cited 31 st August, 2006). Available from: http://www.express-scripts.com/ourcompany/news/ outcomesresearch/onlinepublications/gdur/gdur.pdf#search='generic%20 dispensing.
15. Nguyen, A. (2007). What is the range of policies that can be used to promote the use of generic medicines indeveloping and transitional countries? World Health Organization/Health Action International (unpublished document).
16. Ministry of Health Malaysia (2006). National Medicines Policy of Malaysia, Ministry of Health, Putrajaya, Malaysia.
17. Biga, J., Taboulet, F., Lapeyre-Mestre, M., Duguet, A. M., Vincent, S. & Montastruc, J. L. (2005). Prescribing drugs by international non-proprietary name: The perception of health and non-health professionals. Therapie 60(4), 401-407.
18. Lim, T. O., Ding, L. M., Morad, Z., Suleiman, A. B., Kew, S.T., Maimunah, A. H. & Rugayah, B. (2000). Distribution of blood glucose in a national sample of Malaysian adults. Med. J. Malaysia 55, 65-77.
19. Lim, T. O. & Morad, Z. (2004). Prevalence, awareness, treatment and control of hypertension in Malaysian adult population: Results from the national health morbidity survey 1996 hypertension study group. Singapore Med. J. 45(1), 20-27.
20. Sarojini, S. & Lim, T. O., (eds.) (2006). Malaysian Statistics On Medicine 2004, Kuala Lumpur, Malaysia, available at: www.crc.gov.my/ nmus.
21. Thomas, M. (2007). Consumers' perceptions of generic medicines and their experiences in community pharmacies in Malaysia. Honour Thesis, School of Pharmacy and Medical Sciences, University of South Australia.
22. Haas, J. S., Phillips, K. A., Gerstenberger, E. P, & Segar, A. C. (2005). Potential savings from substituting generic drugs for brand-name drugs: Medical expenditure panel survey, 1997-2000. Ann. Intern. Med. 142, 891-897.
23. Shrank, W. H., Hoang, T., Ettner, S. L., Glassman, P. A., Nair, K., Delapp, D., Dirstine, J., Avorn, J. & Asch, S. M. (2006). The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch. Intern. Med. 166, 332-337.
24. Mott, D. A. & Cline, R. R. (2002). Exploring generic drug use behavior: The role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med. Care 40, 662-674.
25. Birkett, D. J. (2003). Generics - equal or not? Aust. Prescr. 26, 85-87.
26. Hassali, A. & Stewart, K. (2004). Quality use of generic medicines. Aust. Prescr. 27, 80-81.
27. Babar, Z. U., Ibrahim, M. I. M. & Hassali, M. A. (2007). Development of pharmaceutical industry, innovation and public health: Case studies from Malaysia and Pakistan. Pharmaceutical Policy Conference, Zeist, The Netherlands, 19-21st September.
28. Ford N. & Hoen, E. T. (2002). Generic medicines are not substandard medicines. The Lancet 359, 1351, 13th April.